EN DE
Watch Panagene Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Panagene Inc (046210) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Panagene Inc stock KRW 480, price KRW 1,071, that is 55.1% below the price, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7046210001

PI Panagene Inc logo Thin data Nov 3, 2026

Panagene Inc

046210 · KQ
Very expensive, weak quality

Our calculation puts a fair price 55% below what the stock costs today.

Low debt
Revenue last quarter 72% below a year ago.
Fair value 480.36 KRW · Strongly overvalued (−55.1%)
Quality 26/100
Weak Growth (revenue 5y −1.5 %/yr in KRW)
Loss-making · -18.8% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 12/100 · thin data
Thin data
Watch Panagene Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6,190 KRW 999.00 KRW Fair Value 480.36 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range 999.00 KRW – 6,190 KRW · fair‑value band 317.04 KRW – 600.45 KRW · the 1,071 KRW price screens above the 480.36 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Panagene in your weekly email

Every Wednesday you see whether Panagene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Panagene Inc. develops products in the field of molecular diagnostics in South Korea.

Show moreShow less

Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases.

The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The company was formerly known as Koram Panagene Ltd. and changed its name to Panagene Inc. in January 2009.

Panagene Inc. was incorporated in 1976 and is based in Daejeon, South Korea.

Stock analysis

Panagene Inc (046210) currently trades at 1,071 KRW, while our model-based Fair Value estimate is 480.36 KRW, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 317.04 KRW (bear) to 600.45 KRW (bull), the price of 1,071 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Panagene Inc reported revenue of 15.0B KRW in FY2025 versus 15.6B KRW in FY2021, a compound −0.9%/yr. Reported net income was −3.1B KRW in FY2025.

Key figures

Market cap 57.2B KRW (≈ $42.0M) Micro · P/S ratio 1.92 · Net margin −18.8% · Return on equity −441% · Return on assets (EBIT) 2.1% (5-year average) · Operating margin −12.0% · Revenue (TTM) 29.9B KRW · Revenue growth (YoY) −72.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 60% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at −55%, 046210 screens richer than that median.

Fair Value models

Bear 317.04 KRW Fair Value 480.36 KRW Bull 600.45 KRW
Price 1,071 KRW · Downside -55.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 317.04 KRW 480.36 KRW 600.45 KRW 53
All 1 models by family
Asset-Based
NCAV (Graham) 317.04 KRW 480.36 KRW 600.45 KRW 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 14
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 9
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+14.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic). Over 10 years: +9.8% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
31.7% (2020) → −22.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

046210 screens overvalued: fair value 55% below the price. Compare with MEDIPOST Co →

Compare Panagene Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2277 stocks

Beats the sector median on 3/9 measures
Overall it trails its sector peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −55.1% · Below median
Profitability
Return on assets −3.4% · Below median
Net margin (12 months) −18.8% · Bottom 25%
Operating margin (12 months) −12.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −72.2% · Bottom 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 0.79× · Cheapest 25%
P/S (12 months) 1.92× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 18
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Purple Biotech Ltd KTOV 0.0100 ILS 0.0160 ILS +60% vs 046210
Cell Biotech Co 049960 14,630 KRW 15,078 KRW +3% vs 046210
AbbVie Inc ABBV $291.31 $259.62 −11% vs 046210
Biotoxtech Co 086040 2,185 KRW 1,916 KRW −12% vs 046210
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs 046210
Bioneer Corporation 064550 6,350 KRW 3,547 KRW −44% vs 046210
Eli Lilly and Company LLY $1,354 $749.92 −45% vs 046210
MEDIPOST Co 078160 8,480 KRW 3,576 KRW −58% vs 046210
Macrogen, Inc 038290 11,000 KRW 4,457 KRW −59% vs 046210
Pluri Inc PSTI 3.55 ILS 0.9600 ILS −73% vs 046210

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Panagene Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Panagene Inc Fair Value". https://www.fairvalue-calculator.com/stock/046210

Frequently asked questions

Is Panagene Inc (046210) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 480.36 KRW versus a price of 1,071 KRW, about 55% lower (overvalued).
What is the fair value of 046210?
Our model-based fair value for Panagene Inc is 480.36 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 1,071 KRW.
What is the quality score of 046210?
Panagene Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Panagene Inc (046210)?
Our model-based price target is the fair value of 480.36 KRW (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 317.04 KRW, optimistic scenario 600.45 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Panagene Inc stock forecast for 2026?
Our models put fair value at 480.36 KRW, about 55% lower versus a price of 1,071 KRW (overvalued). Cautious scenario 317.04 KRW, optimistic scenario 600.45 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Panagene Inc (046210)?
Panagene Inc reported trailing-twelve-month revenue of about 29.9B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Panagene Inc (046210)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Panagene Inc it is 480.36 KRW per share (as of Nov 3, 2026), against a price of 1,071 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Panagene Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 046210 trades above its calculated fair value: price 1,071 KRW, fair value 480.36 KRW, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 046210?
No. The price is what the market pays today (1,071 KRW); the fair value is what the company's own numbers justify (480.36 KRW). For Panagene Inc the two are 590.64 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Panagene Inc worth?
The market values Panagene Inc at about 57.2B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 1,071 KRW; our models calculate a fair value of 480.36 KRW per share.
What do the bullish and bearish scenarios say about 046210?
Our models span a range for Panagene Inc: cautious scenario 317.04 KRW, base 480.36 KRW, optimistic 600.45 KRW per share (as of Nov 3, 2026, price 1,071 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Panagene Inc (046210)?
Balance-sheet figures for Panagene Inc (as of Nov 3, 2026): return on equity −441.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 046210 from its 52-week high?
Panagene Inc trades at 1,071 KRW, about 60% below its 52-week high of 2,650 KRW and 7% above the low of 999.00 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 480.36 KRW is for.
Which stocks are comparable to Panagene Inc?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Panagene Inc stock attractive at the current price?
The data as of Nov 3, 2026: price 1,071 KRW, calculated fair value 480.36 KRW (−55%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 046210 calculated?
We run Panagene Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 480.36 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Panagene Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Panagene Inc (046210)?
The closing price on Nov 6, 2026 was 1,071 KRW. Our model-based fair value is 480.36 KRW, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Panagene Inc right now?
The price sits above even our optimistic bull case (600.45 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (317.04 KRW to 600.45 KRW) leaves room in how you read the outcome.

Key figures of Panagene Inc

How large is the market capitalisation of Panagene Inc (046210)?
The market capitalisation of Panagene Inc is 57.2B KRW (≈ $42.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Panagene Inc (046210)?
The price-to-sales ratio of Panagene Inc is 1.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Panagene Inc (046210)?
The net margin of Panagene Inc is −18.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Panagene Inc (046210)?
The return on equity (ROE) of Panagene Inc is −441% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Panagene Inc (046210)?
On an EBIT basis the return on assets of Panagene Inc is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Panagene Inc (046210)?
The operating margin of Panagene Inc is −12.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Panagene Inc (046210)?
Revenue at Panagene Inc is growing −72.2% versus a year earlier (3y avg +2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Panagene Inc (046210) generate?
The free cash flow of Panagene Inc is −2.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Panagene Inc (046210) carry?
The net debt of Panagene Inc is 12.8B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Panagene Inc in the live analysis

One click puts Panagene Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.